Silencing of p16 protein expression through epigenetic mechanisms, or because of a germline mutation, has been suspected to play a crucial role in the progression of intraductal proliferative lesions [56] and has been associated with breast cancer risk, particularly in young women [57]. The gene discussed is CDKN2A; the disease is breast carcinoma.